What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?
Clémence Lacroix(Inserm), Olivier Blin(Aix-Marseille Université), Frank Rouby(Inserm), Arnaud Zalta(Inserm), Laurence Attolini(Inserm), Joëlle Micallef(Assistance Publique Hôpitaux de Marseille), Romain Guilhaumou(Inserm), Élisabeth Jouve(Inserm), Isabelle Alleman-Brimault(Inserm), Catherine Cassé‐Perrot(Inserm)
Cited by 16
Related Papers
Multicenter Prospective Study of Children With Sickle Cell Disease: Radiographic and Psychometric Correlation
|Journal of Child Neurology|2000|244
Use of proton pump inhibitors in adults in France: a nationwide drug utilization study
|European Journal of Clinical Pharmacology|2019|130
French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic
|European Annals of Otorhinolaryngology Head and Neck Diseases|2020|76
Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database
|Journal of the Neurological Sciences|2019|60
Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
|Clinical Pharmacology & Therapeutics|2021|48